NCT05576298View on ClinicalTrials.gov

A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

March 21, 2022

Study Completion Date

March 21, 2022

Conditions
Type 2 Diabetes
Interventions
BIOLOGICAL

Insulin degludec injection, RD15003

single dose, s.c. injection

BIOLOGICAL

Insulin degludec, Tresiba

single dose, s.c. injection

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT05576298 - A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects | Biotech Hunter | Biotech Hunter